343 reports of this reaction
1.5% of all EPOPROSTENOL SODIUM reports
#18 most reported adverse reaction
FLUID RETENTION is the #18 most commonly reported adverse reaction for EPOPROSTENOL SODIUM, manufactured by GlaxoSmithKline LLC. There are 343 FDA adverse event reports linking EPOPROSTENOL SODIUM to FLUID RETENTION. This represents approximately 1.5% of all 22,890 adverse event reports for this drug.
Patients taking EPOPROSTENOL SODIUM who experience fluid retention should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FLUID RETENTION is a less commonly reported adverse event for EPOPROSTENOL SODIUM, but still significant enough to appear in the safety profile.
In addition to fluid retention, the following adverse reactions have been reported for EPOPROSTENOL SODIUM:
The following drugs have also been linked to fluid retention in FDA adverse event reports:
FLUID RETENTION has been reported as an adverse event in 343 FDA reports for EPOPROSTENOL SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
FLUID RETENTION accounts for approximately 1.5% of all adverse event reports for EPOPROSTENOL SODIUM, making it a notable side effect.
If you experience fluid retention while taking EPOPROSTENOL SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.